UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

Neurotherapeutics, 2024-09, p.e00378, Article e00378

2024

Volltextzugriff (PDF)

Analysis of Serious Infections and Malignancy Risk in Myasthenia Gravis: A US Claims Database Study (P10-11.007)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P10-11.008)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

The use of stinging nettle tea (Urtica sp.) to control Aulacorthum solani and Macrosiphum euphorbiae on Ranunculus asiaticus

Folia Horticulturae, 2023-12, Vol.35 (2), p.287-296

2023

Volltextzugriff (PDF)

Potential of basic substances in plant protection to reduce Podosphaera pannosa in cut roses

Journal of plant diseases and protection (2006), 2023-06, Vol.130 (3), p.571-578

2023

Volltextzugriff (PDF)

Studies on the potential of the basic substance chitosan in managing Podosphaera pannosa on cutting roses and Erysiphe polygoni on French hydrangea

Journal of plant diseases and protection (2006), 2023-06, Vol.130 (3), p.579-586

2023

Volltextzugriff (PDF)

Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-5.014)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

The relationship between cognition and functioning in schizophrenia: A semi-systematic review

Schizophrenia research. Cognition, 2022-03, Vol.27, p.100217-100217, Article 100217

2022

Volltextzugriff (PDF)

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study

The Lancet. Psychiatry, 2021-03, Vol.8 (3), p.191-201

2021

Volltextzugriff (PDF)

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe

Social Psychiatry and Psychiatric Epidemiology, 2021-03, Vol.56 (3), p.409-416

2021

Volltextzugriff (PDF)

S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL

Schizophrenia bulletin, 2020-05, Vol.46 (Supplement_1), p.S47-S47

2020

Volltextzugriff (PDF)

Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study

Alzheimer's research & therapy, 2020-04, Vol.12 (1), p.38-38, Article 38

2020

Volltextzugriff (PDF)

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial

Clinical drug investigation, 2020-04, Vol.40 (4), p.377-385

2020

Volltextzugriff (PDF)

Alzheimer’s Treatment: Real-World Physician Behavior Across Countries

Advances in therapy, 2020-02, Vol.37 (2), p.894-905

2020

Volltextzugriff (PDF)

Alzheimer’s Diagnosis: Real-World Physician Behavior Across Countries

Advances in therapy, 2020-02, Vol.37 (2), p.883-893

2020

Volltextzugriff (PDF)

Authors’ Response

Journal of forensic sciences, 2019-07, Vol.64 (4), p.1287-1287

2019

Volltextzugriff (PDF)

Authors' Response

Journal of forensic sciences, 2019-07, Vol.64 (4), p.1287

2019

Volltextzugriff (PDF)

Authors' Response

Journal of forensic sciences, 2019-07, Vol.64 (4), p.1287-1287

2019

Volltextzugriff (PDF)

Authors’ Response

Journal of forensic sciences, 2019-07, Vol.64 (4), p.1287-1287

2019

Volltextzugriff (PDF)

Authors’ Response

Journal of forensic sciences, 2019-07, Vol.64 (4), p.1287-1287

2019

Volltextzugriff (PDF)

S27. EFFICACY, SAFETY, AND PHARMACOKINETICS OF BI 425809 ONCE DAILY IN PATIENTS WITH SCHIZOPHRENIA: METHODOLOGY OF A RANDOMIZED TRIAL

Schizophrenia bulletin, 2019-04, Vol.45 (Supplement_2), p.S315-S316

2019

Volltextzugriff (PDF)

S30. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERIZED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: A RANDOMIZED TRIAL METHODOLOGY

Schizophrenia bulletin, 2019-04, Vol.45 (Supplement_2), p.S316-S317

2019

Volltextzugriff (PDF)

DNA Barcoding in Forensic Entomology – Establishing a DNA Reference Library of Potentially Forensic Relevant Arthropod Species

Journal of forensic sciences, 2019-03, Vol.64 (2), p.593-601

2019

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Male
(16)
Neurosciences & Neurology
(14)
Animals
(13)
Humans
(13)
Biological And Medical Sciences
(11)
Female
(11)
Neurosciences
(11)
Psychology. Psychoanalysis. Psychiatry
(9)
Clinical Neurology
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Middle Aged
(7)
Pharmacology & Pharmacy
(7)
Rats
(7)
Adult
(6)
Aged
(6)
Alzheimer's Disease
(6)
Medicine
(6)
Medicine & Public Health
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

Analysis of Serious Infections and Malignancy Risk in Myasthenia Gravis: A US Claims Database Study (P10-11.007)

Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P10-11.008)

The use of stinging nettle tea (Urtica sp.) to control Aulacorthum solani and Macrosiphum euphorbiae on Ranunculus asiaticus

Potential of basic substances in plant protection to reduce Podosphaera pannosa in cut roses

Studies on the potential of the basic substance chitosan in managing Podosphaera pannosa on cutting roses and Erysiphe polygoni on French hydrangea

Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-5.014)

Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)

The relationship between cognition and functioning in schizophrenia: A semi-systematic review

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe

S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL

Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial

Alzheimer’s Treatment: Real-World Physician Behavior Across Countries

Alzheimer’s Diagnosis: Real-World Physician Behavior Across Countries

Authors’ Response

Authors' Response

Authors' Response

Authors’ Response

Authors’ Response

S27. EFFICACY, SAFETY, AND PHARMACOKINETICS OF BI 425809 ONCE DAILY IN PATIENTS WITH SCHIZOPHRENIA: METHODOLOGY OF A RANDOMIZED TRIAL

S30. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERIZED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: A RANDOMIZED TRIAL METHODOLOGY

DNA Barcoding in Forensic Entomology – Establishing a DNA Reference Library of Potentially Forensic Relevant Arthropod Species

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study

Suchergebnisse filtern